Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist

Journal of Clinical Pharmacology

Volumn 43, Issue 1, 2003, Pages 15-22

  Van Giersbergen, Paul L M ^a   Popescu, Gabriela ^b   Bodin, Frédéric ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b APEX Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; RO 47 8634; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER FAILURE; MALE; SCORING SYSTEM; STATISTICAL ANALYSIS;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; L-LACTATE DEHYDROGENASE; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 0037214229     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002239701     Document Type: Article

References (31)

1. Haynes WG, Webb DJ: The endothelin family of peptides: Local hormones with diverse roles in health and disease? Clin Sci 1993;84:485-500.
2. Kedzierski RM, Yanagisawa M: Endothelin system: The double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001;41:851-876.
3. Stewart DJ, Levy RD, Cernacek P, Langleben D: Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991;114:464-469.
4. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-509.
5. Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, et al: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-641.
6. Clozel M, Breu V, Gray GA, Kalina B, Löffler B-M, Burri K, et al: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-235.
7. Rubin LJ: Primary pulmonary hypertension. Chest 1993;104:236-250.
8. Ellahham SH, Charlon V, Abassi Z, Calis KA, Choucair WK: Bosentan and the endothelin system in congestive heart failure. Clin Cardiol 2000;23:803-807.
9. Kiowski W, Suetsch G, Hunziker P, Muller P, Kim J, Oechslin E, et al: Evidence of endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-736.
10. Weber C, Schmitt R, Bimboeck H, Hopfgartner G, van Marle SP, Peeters PAM, et al: Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996;60:124-137.
11. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H, Meyer J, et al: Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol 1999;39:703-714.
12. Dingemanse J, Bodin F, Weidekamm E, Kutz K, van Giersbergen P: Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 2002;42:283-289.
13. Weber C, Gasser R, Hopfgartner G: Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Disp 1999;27:810-815.
14. Dingemanse J, van Giersbergen PLM: Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int J Clin Pharmacol Ther 2002;40:310-316.
15. van Giersbergen PLM, Halabi A, Dingemanse J: Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 2002;53:589-595.
16. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP: Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-528.
17. Auletta M, Oliviero U, Iasiuolo L, Scherillo G, Antoniello S: Pulmonary hypertension associated with liver cirrhosis: An echocardiographic study. Angiology 2000;51:1013-1020.
18. Rubin LJ, Badesch DB, Barst R, Galié N, Black CM, Keogh A, et al: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
19. Child CG: The Liver and Portal Hypertension. Philadelphia: W. B. Saunders, 1964.
20. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Brit J Surg 1973;60:646-649.
21. Lausecker B, Hess B, Fischer G, Mueller M, Hopfgartner G: Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection. J Chromatogr B 2000;749:67-83.
22. Gibaldi M, Perrier D: Pharmacokinetics. New York: Marcel Dekker, 1982.
23. Morgan DJ, McLean AJ: Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. Clin Pharmacokinet 1995;29:370-391.
24. Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, et al: Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997;62:272-278.
25. Sokol SI, Cheng A, Frishman WH, Kaza CS: Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol 2000;40:11-30.
26. Benet L, Hoener B-A: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-121.
27. George J, Murray M, Byth K, Farrell GC: Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995;21:120-128.
28. Rodighiero V: Effects of liver disease on pharmacokinetics: An update. Clin Pharmacokinet 1999;37:399-431.
29. Huang YS, Lee SD, Deng JF, Wu JC, Lu RH, Lin YF, et al: Measuring lidocaine metabolite monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993;19:140-147.
30. McConnell JB, Powell-Jackson PR, Davis M, Williams R: Use of liver function tests as predictors of rifampicin metabolism in cirrhosis. Quarterly J Med 1981;197:77-82.
31. Zilly W, Breimer DD, Richter E: Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 1977;20:287-293.